Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SUBLOCADE Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

NCT02926482
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Prescriber Recruitment Bundle (PRB)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Tallahassee, Florida • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

Onsite Buprenorphine Treatment at Syringe Exchange Programs

NCT03150173
View directory record Official record
Conditions
Opiate Addiction
Interventions
Onsite treatment, Enhanced referral, Buprenorphine
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence

NCT00548275
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Enhanced Sexual Risk Management, Standard Sexual Risk Management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

NCT00000230
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder

NCT06086275
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

NCT01046539
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
RDC-0313 + Buprenorphine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 5, 2026, 7:38 AM EDT
Recruiting No phase listed Observational

fMRI and Opioid Abstinence

NCT06651333
View directory record Official record
Conditions
Drug Use Disorder, Opioid Dependence, Opioid-Related Disorders, Opioid Use, Opioid Abuse
Interventions
fMRI
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Hartford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Buprenorphine Detoxification - BBDVI - 19

NCT00000237
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.

NCT00315445
View directory record Official record
Conditions
Back Pain
Interventions
Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
12
States / cities
Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13

NCT00000231
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance for Opioid Addicts - 1

NCT00000202
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 5, 2026, 7:38 AM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase IX - 14

NCT00000232
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
22 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Not applicable Interventional

tAN for PTSD and OUD in Buprenorphine Therapy

NCT06130501
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Opioid Use Disorder
Interventions
Sparrow Ascent tAN, Sparrow Ascent Active Sham
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cape Girardeau, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 5, 2026, 7:38 AM EDT
Not listed Phase 2 Interventional

Sublingual Buprenorphine for Chronic Pain

NCT00612287
View directory record Official record
Conditions
Chronic Pain
Interventions
buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 5, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

NCT03254459
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Buprenorphine Sublingual Spray, Morphine, Oxycodone Hydrochloride, Zofran
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Pasadena, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

NCT03608696
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Up to 4 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 5, 2026, 7:38 AM EDT
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 5, 2026, 7:38 AM EDT
Completed Not applicable Interventional

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

NCT05108935
View directory record Official record
Conditions
Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions
Suboxone, Truvada, Mavyret
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 5, 2026, 7:38 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 5, 2026, 7:38 AM EDT